Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE 2nd Edition of Int'l Headache Classification Previewed: Pfizer Seminar
December 15, 2003
-
ARCHIVE Basic Policy for Next NHI Pricing System Reform Presented
December 15, 2003
-
ARCHIVE NEW PRODUCTS
December 15, 2003
-
ARCHIVE DIAGNOSTIC NEWS IN BRIEF
December 15, 2003
-
ARCHIVE Price Discrepancy Rate Marks 6.3%: Price Survey
December 15, 2003
-
ARCHIVE Videophone-based Drug Sales to Be Approved
December 15, 2003
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
December 15, 2003
-
ARCHIVE SSP: Sales of OTC Products Down 4.8% to \23.8 Bil.
December 8, 2003
-
ARCHIVE Semi-annual Business Result
December 8, 2003
-
ARCHIVE Nikken Chemicals: 30%-decrease in Sales of Theodur Hurts Sales, Profits
December 8, 2003
-
ARCHIVE Sundrug: Sales, Ordinary Profits Up 16.5%, 3.8% Respecticely
December 8, 2003
-
ARCHIVE ON THE MOVE
December 8, 2003
-
ARCHIVE Kobayashi: Operating Profits Down 4.4%, Hurt by Cool Summer
December 8, 2003
-
ARCHIVE BIO-Asia Clinical Stage Partnering Conference to Give Makers Good Chance: Mr Tanaka, Consultant
December 8, 2003
-
ARCHIVE OTC NEWS IN BRIEF
December 8, 2003
-
ARCHIVE Kaken to Remain Independent, Focus on Niche Markets: President Inui
December 8, 2003
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
December 8, 2003
-
ARCHIVE EU's Clinical Trial Directive Discussed: Quintiles Seminar
December 8, 2003
-
ARCHIVE DIAGNOSTIC NEWS IN BRIEF
December 8, 2003
-
ARCHIVE Resistance to Use of Contract MRs Weakening: Fuji-keizai Survey
December 8, 2003
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…